ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2690

Plasma D-Dimer Levels Are More Frequently Elevated in Limited Than Diffuse Cutaneous Systemic Sclerosis but Do Not Reflect Disease Duration or Vasculopathy

Anna Gill1, Svetlana I. Nihtyanova2, Pratima Chowdary3 and Christopher Denton1, 1Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, 2Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, 3Department of Haematology, Royal Free Hospital, London, United Kingdom

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: scleroderma and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

D-dimers are degradation products of cross linked fibrin and are biomarkers of activation of the coagulation system. Plasma D-dimer levels can be raised in physiological and pathological non-thrombotic conditions and are thought to be related to a pro-thrombotic state.

Studies have shown raised D-dimer levels in systemic sclerosis (SSc), particularly in diffuse SSc (DcSSc). An association between raised D-dimer level and peripheral ischaemia in SSc has also been described, suggesting that this could be related to a pro-thrombotic state.

Methods:

Blood samples were drawn from 60 outpatients who met the 2013 ACR/EULAR classification criteria for SSc. Samples were analysed for Factor XIII (FXIII) activity (U/dL), D-dimer (ng/ml), and fibrinogen (g/L) levels, and activated partial thromboplastin time (aPTT) (s). Clinical data gathered included age, gender, disease subtype, autoantibody details, duration of SSc and complications of SSc. Associations of demographic and clinical characteristics with FXIII were assessed using linear regression, while associations with D-dimer were analysed using Fisher’s exact test and logistic regression.

Results:

Of the 60 patients assessed, 83.3% were female. Age range was 20-82 years, with a mean age of 60.4 years. In terms of SSc subtype, 51.7% had limited SSc (LcSSc). The duration of SSc ranged from 0.62 to 50.6 years, with a mean duration of 14 years. Antibody status was collected; 36.7% were anti-centromere antibody positive, 11.7% were anti-Scl 70 antibody positive, 16.7% were anti-RNA polymerase antibody positive, and 35% had other positive autoantibodies. An overlapping rheumatological condition was found in 15% of patients. Of all patients, 25% had diagnosis of pulmonary fibrosis (PF), 31.7% had a history of digital ulceration (DU), and 8.3% had active DU at the time of blood draw.

D-dimers were raised in 62.7% of the patients. Raised D-dimer was seen more frequently in lcSSc patients (77.4%) compared to dcSSc (46.4%, p=0.017). In addition, older age increased the odds of having raised D-dimer (OR 1.1, p=0.001). Higher fibrinogen was associated with increased odds for raised D-dimer (OR 6.5, p=0.001). There was no association between raised D-dimer level and PF, current or previous digital ulceration (DU).

Factor XIII activity was positively associated with age (for each year older, this increased by 0.75, p=0.007) but did not associate with diffuse subset, disease duration, autoantibody specificity, fibrinogen level or APTT. There was evidence for a weak association between raised D-dimer and FXIII, where patients with raised D-dimer had on average 13.4 U/dL higher FXIII levels compared to those with normal D-dimer, p=0.089.

Conclusion:

This study confirms that D-dimer levels are frequently elevated in SSc. In contrast to previous studies, our data suggest raised D-dimer level is more commonly associated with LcSSc.

There was no correlation between raised D-dimer level and duration of SSc. This is in contrast with other inflammatory markers such as CRP, which are raised in early SSc only. There was no association between D-dimer level and current or previous DU, suggesting that this feature of vascular dysfunction in SSc is not related to a thrombotic state.


Disclosure: A. Gill, None; S. I. Nihtyanova, None; P. Chowdary, None; C. Denton, Actelion, Pfizer, GlaxoSmithKline, Bayer, Sanofi-Aventis, Boehringer Ingelheim, Genentech-Roche, CSL Behring, Biogen, 5,Actelion, GlaxoSmithKline, Bayer, Genentech-Roche, CSL Behring, 2.

To cite this abstract in AMA style:

Gill A, Nihtyanova SI, Chowdary P, Denton C. Plasma D-Dimer Levels Are More Frequently Elevated in Limited Than Diffuse Cutaneous Systemic Sclerosis but Do Not Reflect Disease Duration or Vasculopathy [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/plasma-d-dimer-levels-are-more-frequently-elevated-in-limited-than-diffuse-cutaneous-systemic-sclerosis-but-do-not-reflect-disease-duration-or-vasculopathy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/plasma-d-dimer-levels-are-more-frequently-elevated-in-limited-than-diffuse-cutaneous-systemic-sclerosis-but-do-not-reflect-disease-duration-or-vasculopathy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology